Hyperglycemia vs. Insulin Effect—PET’s Dual Threats

Sugar, Sugar: Both hyperglycemia and insulin exposure degrade [18F]FDG PET image quality, although they do so via distinct physiologic mechanisms that require different management strategies.

Understanding that difference is critical. And as Phil Mulugeta, MD, reminded us in a recent AJR Expert Panel Narrative Review, the insulin effect is often more detrimental to a scan than the hyperglycemia, itself.

The Competition—Hyperglycemia

• Mechanism: Elevated serum glucose levels compete directly with FDG for cellular transport via glucose transporter (GLUT) proteins and phosphorylation by hexokinase.
• Impact: This competitive inhibition reduces tumor-to-background contrast and can lower SUVs in tumors and the brain.
• Silver Lining? Despite high glucose, tumor FDG uptake often remains robust enough for accurate visual interpretation, especially at levels below 200 mg/dL.

The Diversion—Insulin Effect

• Mechanism: The presence of short-acting exogenous insulin or endogenous insulin, triggered by a recent meal, upregulates GLUT-4.
• Impact: Mulugeta et al. note that this “shunts” the injected FDG into skeletal muscles and the myocardium, diverting it away from potential malignancies.
• Danger! This effect can render a scan completely non-diagnostic—even when the measured blood glucose level appears acceptable
  • A patient scanned 1.5 hours after eating could show a false negative, due to diffuse muscle uptake masking hypermetabolic metastases.

The Trap: Administering correctional insulin immediately before a scan in an attempt to fix hyperglycemia often backfires. Sure, it’ll lower the sugar number, but it triggers the far more damaging insulin effect, resulting in abnormal tracer biodistribution.

• The Consensus: If correctional insulin must be used for levels >300 mg/dL, it should be administered subcutaneously (never IV!) with a mandatory 4-hour delay before FDG injection to allow the insulin effect to subside.

RadFYI: Optimal preparation relies on two pillars: achieving euglycemia to prevent competitive inhibition and maintaining basal-only insulin levels to avoid tracer diversion to muscle.